Unassociated Document
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): August 6, 2010
Nutra
Pharma Corp.
(Exact
name of registrant as specified in its charter)
California
|
000-32141
|
91-2021600
|
(State
or jurisdiction of
|
(Commission
|
(I.R.S.
Employer
|
incorporation
or organization)
|
File
Number)
|
Identification
No.)
|
2776
University Drive
Coral
Springs, Florida 33065
(Address
of principal executive offices) (Zip Code)
Registrant's
telephone number: 954 509-0911
(Former
name or former address, if changed since last report)
Nutra
Pharma Corp. is referred to herein as “we”, “our” or “us.
Item 2.02. Results
of Operations and Financial Condition
On August
6, 2010, we issued a press release announcing our sales of $150,158 for our
second fiscal quarter ended June 30, 2010.
A copy of
the press release is attached as Exhibit 99.1 and incorporated herein by
reference.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit
99.1 Press Release
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the Registrant
has duly caused this Current Report on Form 8-K to be signed on its behalf by
the undersigned hereunto duly authorized.
DATED:
August 6, 2010
|
Nutra
Pharma Corp.
|
|
|
|
|
|
|
|
|
|
|
/s/
|
Rik
Deitsch
|
|
|
|
Rik
Deitsch, President, Chief Executive Officer
|
|
|
|